1. Executive Summary 2. Introduction 2.1 Overview of Anticoagulants 2.1.1 Types of Anticoagulants 2.1.2 Novel Oral Anticoagulants 3. Global Market Analysis 3.1 Global Anticoagulants Market Analysis 3.1.1 Global Anticoagulants Market by Value 3.1.2 Global Anticoagulants Market Share by Treatment 3.1.3 Global Anticoagulants Market Share by Segment (Oral Anticoagulants and others) 3.1.4 Global Anticoagulants Market Share by Products (Lovenox, Arixtra, Xarelto, Eliquis, Pradaxa, and Savaysa) 4. Global Anticoagulants Product Analysis 4.1 Injectable Anticoagulants Product Analysis 4.1.1 Global Lovenox Market by Value 4.1.2 Global Arixtra Market by Value 4.2 Oral Anticoagulants Product Analysis 4.2.1 Global Xarelto Market by Value 4.2.2 Global Eliquis Market by Value 4.2.3 Global Pradaxa Market by Value 4.2.4 Global Savaysa Market by Value 5. Regional Analysis 5.1 The US Anticoagulants Market Analysis 5.1.1 The US Anticoagulants Market by Value 5.1.2 The US Anticoagulants Market by Products (Xarelto, Eliquis, Pradaxa, and Savaysa) 5.1.3 The US Xarelto Market by Value 5.1.4 The US Eliquis Market by Value 5.1.5 The US Pradaxa Market by Value 5.1.6 The US Savaysa Market by Value 6. Competitive Landscape 6.1 Global Top Oral Anticoagulants by Sales 6.2 Global Anticoagulants Market Players by Product Comparison 7. Company Profile 7.1 Bayer Group 7.1.1 Business Overview 7.1.2 Financial Overview 7.1.3 Business Strategy 7.2 BMS/Pfizer 7.2.1 Business Overview 7.2.2 Financial Overview 7.2.3 Business Strategy 7.3 Boehringher Ingelheim 7.3.1 Business Overview 7.3.2 Financial Overview 7.3.3 Business Strategy 7.4 Daiichi Sankyo 7.4.1 Business Overview 7.4.2 Financial Overview 7.4.3 Business Strategy List of Figures Figure 1: Types of Anticoagulants Figure 2: Global Anticoagulants Market by Value; 2013-2017 (US$ Billion) Figure 3: Global Anticoagulants Market by Value; 2017-2022 (US$ Billion) Figure 4: Global Anticoagulants Market Share by Treatment; 2015 (Percentage, %) Figure 5: Global Anticoagulants Market Share by Segment; 2017 (Percentage, %) Figure 6: Global Anticoagulants Market Share by Products; 2017 (Percentage, %) Figure 7: Global Lovenox Market by Value; 2012-2017 (US$ Billion) Figure 8: Global Arixtra Market by Value; 2015-2017 (US$ million) Figure 9: Global Xarelto Market by Value; 2016-2022 (US$ Billion) Figure 10: Global Eliquis Market by Value; 2016-2022 (US$ Billion) Figure 11: Global Pradaxa Market by Value; 2016-2022(US$ Billion) Figure 12: Global Savaysa Market by Value; 2016-2022 (US$ Million) Figure 13: The US Anticoagulants Market by Value; 2016-2022(US$ Billion) Figure 14: The US Anticoagulants Market by Products; 2017 (Percentage, %) Figure 15: The US Xarelto Market by Value; 2016-2022(US$ Billion) Figure 16: The US Eliquis Market by Value; 2016-2022(US$ Billion) Figure 17: The US Pradaxa Market by Value; 2016-2022(US$ Million) Figure 18: The US Savaysa Market by Value; 2016-2022(US$ Million) Figure 19: Global Top Oral Anticoagulants by Sales; 2017 (US$ Billion) Figure 20: Bayer Group Net Sales; 2012-2017 (US$ Billion) Figure 21: Bayer Group Net Sales by Segment; 2017 (Percentage, %) Figure 22: Bayer Group Net Sales by Geography; 2017 (Percentage, %) Figure 23: BMS-Pfizer Alliance Revenue; 2014-2017 (US$ Billion) Figure 24: BMS Revenue by Geography; 2017 (Percentage, %) Figure 25: BMS Revenue by Product; 2017 (Percentage, %) Figure 26: Boehringher Ingelheim Net Sales; 2012-2016 (US$ Billion) Figure 27: Boehringher Ingelheim Net Sales by Geography; 2016 (Percentage, %) Figure 28: Boehringher Ingelheim Net Sales by Business; 2016 (Percentage, %) Figure 29: Daiichi Sankyo Revenue; 2012-2017 (US$ Billion) Figure 30: Daiichi Sankyo Revenue by Geography; 2017 (Percentage, %) Table 1: Unfractionated Heparin v/s Low Molecular Weight Heparin Table 2: List of Intravenous/Subcutaneous Anticoagulants Table 3: List of Oral Anticoagulants (NOCAs) Table 4: Global Anticoagulants Market Players by Product Comparison Table 5: Bayer Group Product and Activities of Pharmaceutical Segment Table 6: Xarelto Research and Development Project (Phase III) Table 7: Boehringher Ingelheim Product Review; 2016